The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Roy G Geronemus - One of the best experts on this subject based on the ideXlab platform.
-
q switched ruby laser therapy of Nevus of Ota
Archives of Dermatology, 1992Co-Authors: Roy G GeronemusAbstract:• Background. —The Q-switched ruby laser has been demonstrated to provide selective photothermolysis of pigmented tissue at a wavelength of 694 nm and a pulse width of 40 ns with dermal penetration. It was used to treat 15 patients with Nevus of Ota involving the face with an age range of 6 to 52 years. Other methods of treatment for the Nevus of Ota have either left scarring or were ineffective. The clinical efficacy of this laser treatment was evaluated in a comparative photographic analysis. Observations. —Complete clearing was noted in four of the 15 patients and a minimum of 50% lightening of the original color in the remaining 11. Ten of the 15 patients were Asian, two were white, two were Hispanic, and one was Indian. The energy fluence used varied between 6 and 10 J/cm 2 , and the number of treatments ranged from 1 to 7. Significant lightening or clearing was found at the higher energy ranges of 9 to 10 J/cm 2 with significantly less lightening noted at the lower energy range of 6 to 8.5 J/cm 2 . No scarring was noted in any of the 15 patients, and some isolated hypopigmentation was noted in one of the subjects. Transient postinflammatory hyperpigmentation of 2 months' duration was noted in only one patient. Conclusion. —Q-switched ruby selective photothermolysis appears to be an effective and safe method of lightening or removing Nevus of Ota.
-
q switched ruby laser therapy of Nevus of Ota
Archives of Dermatology, 1992Co-Authors: Roy G GeronemusAbstract:BACKGROUND: The Q-switched ruby laser has been demonstrated to provide selective photothermolysis of pigmented tissue at a wavelength of 694 nm and a pulse width of 40 ns with dermal penetration. It was used to treat 15 patients with Nevus of Ota involving the face with an age range of 6 to 52 years. Other methods of treatment for the Nevus of Ota have either left scarring or were ineffective. The clinical efficacy of this laser treatment was evaluated in a comparative photographic analysis. OBSERVATIONS: Complete clearing was noted in four of the 15 patients and a minimum of 50% lightening of the original color in the remaining 11. Ten of the 15 patients were Asian, two were white, two were Hispanic, and one was Indian. The energy fluence used varied between 6 and 10 J/cm2, and the number of treatments ranged from 1 to 7. Significant lightening or clearing was found at the higher energy ranges of 9 to 10 J/cm2 with significantly less lightening noted at the lower energy range of 6 to 8.5 J/cm2. No scarring was noted in any of the 15 patients, and some isolated hypopigmentation was noted in one of the subjects. Transient postinflammatory hyperpigmentation of 2 months' duration was noted in only one patient. CONCLUSION: Q-switched ruby selective photothermolysis appears to be an effective and safe method of lightening or removing Nevus of Ota.
Rox R Anderson - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Nevus of Ota by Q-switched ruby laser.
Journal of the American Academy of Dermatology, 1994Co-Authors: Charles R Taylor, Thomas J Flotte, R W Gange, Rox R AndersonAbstract:There are few reports on therapy for Nevus of Ota. Moreover, traditional treatments are largely palliative or risk permanent pigmentary changes and/or scarring. The efficacy of the Q-switched ruby laser (694 nm, 40 nsec) as a therapy for Nevus of Ota was investigated. Nine nevi or portions thereof were irradiated up to six times with 4.5 and/or 7.5 J/cm2 at a mean exposure interval of 3 weeks. Sequential skin biopsy specimens were processed for light microscopy, immunohistochemistry, and electron microscopy. Cosmetic improvement occurred at both doses in the irradiated parts of the six nevi available for follow-up. No appreciable difference was noted between single and multiple treatments. There was no gross scarring. Light microscopy revealed dose-related immediate injury with more melanophages and fewer dermal melanocytes after irradiation in comparison with control areas. Electron microscopic distinction between dermal melanocytes and melanin-laden macrophages was difficult. A monoclonal antibody to human melanosome-specific antigen type 1 (HMSA-1) was used to distinguish between the two cell populations. Our findings suggest that the Q-switched ruby laser is useful for treating Nevus of Ota.
-
treatment of Nevus of Ota by q switched ruby laser
Journal of The American Academy of Dermatology, 1994Co-Authors: Charles R Taylor, Thomas J Flotte, William R Gange, Rox R AndersonAbstract:Background: There are few reports on therapy for Nevus of Ota. Moreover, traditional treatments are largely palliative or risk permanent pigmentary changes and/or scarring. Objective: The efficacy of the Q-switched ruby laser (694 nm, 40 nsec) as a therapy for Nevus of Ota was investigated. Methods: Nine nevi or portions thereof were irradiated up to six times with 4.5 and/or 7.5 J/cm2 at a mean exposure interval of 3 weeks. Sequential skin biopsy specimens were processed for light microscopy, immunohistochemistry, and electron microscopy. Results: Cosmetic improvement occurred at both doses in the irradiated parts of the six nevi available for follow-up. No appreciable difference was noted between single and multiple treatments. There was no gross scarring. Light microscopy revealed dose-related immediate injury with more melanophages and fewer dermal melanocytes after irradiation in comparison with control areas. Electron microscopic distinction between dermal melanocytes and melanin-laden macrophages was difficult. A monoclonal antibody to human melanosome-specific antigen type 1 (HMSA-1) was used to distinguish between the two cell populations. Conclusion: Our findings suggest that the Q-switched ruby laser is useful for treating Nevus of Ota.
J F Pellissier - One of the best experts on this subject based on the ideXlab platform.
-
intracranial meningeal melanocytoma associated with ipsilateral Nevus of Ota case report
Journal of Neurosurgery, 2002Co-Authors: Mariedominique Piercecchimarti, Hicham Mohamed, A Liprandi, Daniele Gambarelli, F Grisoli, J F PellissierAbstract:✓ In this report, the authors review the case of a man with a neurocutaneous syndrome. He presented with an intracerebral melanocytoma associated with a blue Nevus of the scalp; its location and its appearance during childhood supported the diagnosis of a Nevus of Ota. Meningeal melanocytomas are increasingly being diagnosed, but remain rare. Primary meningeal malignant melanoma is the first differential diagnosis to eliminate. Despite their common embryonic origin, the association of a melanocytoma with a Nevus of Ota is rare. A Nevus of Ota exhibits the same melanocytic proliferation and affects the trigeminal nerve territory. An ocular effect is not always observed. In contrast to an ocular lesion, a Nevus of Ota rarely transforms into a malignant melanoma. It is found only among caucasians. During 4 years of follow-up review after surgery, the patient remained asymptomatic. Other than antiepileptic therapy, he received no complementary treatment and cerebral imaging revealed no evidence of recurrence.
Yuanhong Li - One of the best experts on this subject based on the ideXlab platform.
-
a retrospective study of q switched alexandrite laser in treating Nevus of Ota
Dermatologic Surgery, 2011Co-Authors: John Z S Chen, Honghui Xu, Hongduo Chen, Yuanhong LiAbstract:BACKGROUNDThe Q-switched alexandrite laser (QSAL) has been clinically proven to be effective in treating Nevus of Ota, but a large-scale retrospective study with long-term follow-up has never been performed.OBJECTIVETo evaluate the efficacy of the QSAL in treating Nevus of Ota, the laser's long-term
-
a retrospective study of q switched alexandrite laser in treating Nevus of Ota
Dermatologic Surgery, 2011Co-Authors: John Z S Chen, Honghui Xu, Hongduo Chen, Yuanhong LiAbstract:BACKGROUND: The Q-switched alexandrite laser (QSAL) has been clinically proven to be effective in treating Nevus of Ota, but a large-scale retrospective study with long-term follow-up has never been performed. OBJECTIVE: To evaluate the efficacy of the QSAL in treating Nevus of Ota, the laser's long-term side effects, complications associated with the treatments, and the recurrence rate. MATERIALS AND METHODS: Eight hundred six patients (651 female, 155 male) with a diagnosis of Nevus of Ota who had received a series of QSAL (wavelength 755 nm) treatments were recruited. The typical settings were fluences of 3.8 to 4.8 J/cm(2) and a spot size of 3 mm. Follow-ups were conducted via questionnaire with 590 patients who had completed the treatment at least 3 years earlier. RESULTS: Overall, 93.9% of patients achieved complete clearance after an average of 5.2 sessions. All recurrences (0.8%) appeared beyond the previously treated sites. No long-term adverse effects, including hypopigmentation, hyperpigmentation, textural changes, and malignant transformation, were observed. CONCLUSION: The QSAL is a safe and effective modality for treating Nevus of Ota. Recurrence was rare and appeared beyond the previously treated sites. The authors have indicated no significant interest with commercial supporters.
Yufeng Su - One of the best experts on this subject based on the ideXlab platform.
-
meningeal melanocytoma associated with Nevus of Ota analysis of twelve reported cases
World Neurosurgery, 2019Co-Authors: Chiehhsin Wu, Chihhui Chang, Hungpei Tsai, Annshung Lieu, Yufeng SuAbstract:Background Primary melanocytic neoplasms (PMNs) are rare neoplasms, especially within the central nervous system. Meningeal melanocytomas, a subtype of PMN, are even rarer. Nevus of Ota results from the incomplete migration of melanocytes from the neural crest. Synchronous Nevus of Ota and meningeal melanocytoma are infrequently encountered in clinical practice. Objective To evaluate and elucidate 12 cases of synchronous meningeal melanocytoma and Nevus of Ota, thereby improving the understanding of the relationship between these 2 diseases. Methods We reviewed cases and searched the English-language literature from the PubMed database and collected clinical parameters of 12 cases of synchronously occurring Nevus of Ota and meningeal melanocytoma. Results Among the 12 cases, 90.90% and 91.66% of the lesions were located ipsilaterally and supratentorially, respectively. Conclusions Our findings indicated a trend for both types of lesion to be located ipsilaterally and supratentorially. When a patient with Nevus of Ota is found to harbor an intracranial neoplasm, the most likely diagnosis is PMN.